Individualized everolimus treatment for tuberous sclerosis-related angiomyolipoma promotes treatment adherence and response.

ABSTRACT:

Background

Everolimus is a potential alternative to embolization and nephrectomy for managing tuberous sclerosis complex (TSC)-associated renal angiomyolipoma (AML). In 2016, National Health Service England approved its use through regional centres for renal AML ≥30 mm showing interval growth. Evidence of lesion stabilization or reduction after 6 months is mandated for continuation of long-term treatment.

Methods

From November 2016 to June 2021, all potentially eligible adult TSC patients with AML across Yorkshire and Humber were referred for assessment and monitoring. Eligible patients underwent baseline renal magnetic resonance imaging (MRI) assessment and a follow-up MRI scan after 6 months on everolimus. Dose titration was guided by trough levels and lesion responsivenes

SUBMITTER: Chung NKX 

PROVIDER: S-EPMC9214570 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature